{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T13:30:10Z","timestamp":1795095010388,"version":"4.10.2"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n            <jats:title>OBJECTIVES:<\/jats:title>\n            <jats:p>To evaluate and synthesize the existing evidence for the association of angiotensin-II with thromboembolic events.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DATA SOURCES:<\/jats:title>\n            <jats:p>PubMed, Scopus, and CENTRAL databases.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>STUDY SELECTION:<\/jats:title>\n            <jats:p>This systematic review included randomized trials and comparative observational studies that reported on the occurrence of venous and\/or arterial thromboembolic events in adult patients receiving treatment for shock with angiotensin-II vs. a comparator.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DATA EXTRACTION:<\/jats:title>\n            <jats:p>A total of 1689 records were screened by two independent investigators. Seven studies were deemed eligible for inclusion, encompassing 1461 patients. This included two randomized controlled trials and five nonrandomized studies of intervention. Data were extracted independently and in duplicate. Risk of bias assessments were performed using the Risk of Bias 2 and Risk Of Bias In Nonrandomized Studies of Interventions tools.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DATA SYNTHESIS:<\/jats:title>\n            <jats:p>The included studies reported on a variety of individual and composite thromboembolic events as exploratory endpoints. Overall, they demonstrated an elevated risk of bias, predominantly related to confounding, measurement of outcomes and selection of reported results, which precluded quantitative synthesis. Within these limitations, we found that thromboembolic event rates were similar between the angiotensin-II and comparator groups. Venous thromboembolic events were described in 8.8% of patients receiving angiotensin-II and 9.4% of controls, while arterial thromboembolic events were reported in 11.3% and 12.7%, respectively. Total event rates were broadly comparable when utilizing data derived from the primary publications and when adjusted for the U.S. Food and Drug Administration account of trial data.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSIONS:<\/jats:title>\n            <jats:p>Published evidence does not currently support or refute an association between angiotensin-II and an increased risk of venous or arterial thromboembolic events. Given the limited quality of available data, future studies should explicitly define diagnostic and reporting criteria for such events.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ccm.0000000000006433","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T14:00:47Z","timestamp":1729000847000},"page":"1894-1905","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":17,"title":["Angiotensin-II and Thromboembolic Events: A Systematic Review*"],"prefix":"10.1097","volume":"52","author":[{"given":"Rebecca","family":"Caragata","sequence":"first","affiliation":[{"name":"Department of Anaesthesia, Austin Health, Melbourne, VIC, Australia."},{"name":"Department of Critical Care, School of Medicine, University of Melbourne, Melbourne, VIC, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel A.","family":"Johnston","sequence":"additional","affiliation":[{"name":"Department of Anaesthesia, Austin Health, Melbourne, VIC, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian Wen","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Anaesthesia, Austin Health, Melbourne, VIC, Australia."},{"name":"Department of Intensive Care, Austin Health, Melbourne, VIC, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Starkey","sequence":"additional","affiliation":[{"name":"Department of Surgery, Austin Health, Melbourne, VIC, Australia."},{"name":"Victorian Liver Transplant Unit, Austin Health, Melbourne, VIC, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinaldo","family":"Bellomo","sequence":"additional","affiliation":[{"name":"Department of Critical Care, School of Medicine, University of Melbourne, Melbourne, VIC, Australia."},{"name":"Department of Intensive Care, Austin Health, Melbourne, VIC, Australia."},{"name":"Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, VIC, Australia."},{"name":"Data Analytics Research and Evaluation, Austin Hospital, Melbourne, VIC, Australia."},{"name":"Department of Intensive Care, Royal Melbourne Hospital, Melbourne, VIC, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,10,15]]},"reference":[{"key":"R1-20250502","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1056\/NEJMoa1704154","article-title":"Angiotensin II for the treatment of vasodilatory shock.","volume":"377","author":"Khanna","year":"2017","journal-title":"N Engl J Med"},{"key":"R2-20250502","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1177\/1060028018767899","article-title":"A blast from the past: Revival of angiotensin II for vasodilatory shock.","volume":"52","author":"Bissell","year":"2018","journal-title":"Ann Pharmacother"},{"key":"R3-20250502","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1177\/0885066620911601","article-title":"Angiotensin II and vasopressin for vasodilatory shock: A critical appraisal of catecholamine-sparing strategies.","volume":"36","author":"Heavner","year":"2021","journal-title":"J Intensive Care Med"},{"key":"R4-20250502","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40256-018-0297-9","article-title":"FDA approval of angiotensin II for the treatment of hypotension in adults with distributive shock.","volume":"19","author":"Senatore","year":"2019","journal-title":"Am J Cardiovasc Drugs"},{"key":"R5-20250502","article-title":"Prescribing Information: GIAPREZA (Angiotensin II) Injection for Intravenous Infusion.","year":"2017"},{"key":"R6-20250502","article-title":"Summary of product characteristics: GIAPREZA.","year":"2019"},{"key":"R7-20250502","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1053\/j.jvca.2021.07.021","article-title":"Angiotensin II: A review of current literature.","volume":"36","author":"Alam","year":"2022","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"R8-20250502","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1097\/CCM.0000000000002441","article-title":"Clinical experience with IV angiotensin II administration: A systematic review of safety.","volume":"45","author":"Busse","year":"2017","journal-title":"Crit Care Med"},{"key":"R9-20250502","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.chest.2020.08.2074","article-title":"Angiotensin II infusion for shock: A multicenter study of postmarketing use.","volume":"159","author":"Wieruszewski","year":"2021","journal-title":"Chest"},{"key":"R10-20250502","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/0885066620972943","article-title":"A multicenter observational cohort study of angiotensin II in shock.","volume":"37","author":"Smith","year":"2022","journal-title":"J Intensive Care Med"},{"key":"R11-20250502","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"R12-20250502","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R13-20250502","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions.","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"R14-20250502","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/anae.15802","article-title":"A double-blind randomised feasibility trial of angiotensin-2 in cardiac surgery.","volume":"77","author":"Coulson","year":"2022","journal-title":"Anaesthesia"},{"key":"R15-20250502","doi-asserted-by":"crossref","first-page":"e0230","DOI":"10.1097\/CCE.0000000000000230","article-title":"Physiologic response to angiotensin II treatment for coronavirus disease 2019-induced vasodilatory shock: A retrospective matched cohort study.","volume":"2","author":"Leisman","year":"2020","journal-title":"Crit Care Explor"},{"key":"R16-20250502","first-page":"215","article-title":"Angiotensin II infusion and markers of organ function in invasively ventilated COVID-19 patients.","volume":"23","author":"Zangrillo","year":"2021","journal-title":"Crit Care Resusc"},{"key":"R17-20250502","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/10600280221099928","article-title":"Evaluation of the addition of angiotensin II in patients with shock after cardiac surgery at a Veterans affairs medical center.","volume":"57","author":"Bird","year":"2023","journal-title":"Ann Pharmacother"},{"key":"R18-20250502","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/SHK.0000000000002109","article-title":"A pilot study of angiotensin ii as primary vasopressor in critically ill adults with vasodilatory hypotension: The ARAMIS study.","volume":"59","author":"See","year":"2023","journal-title":"Shock"},{"key":"R19-20250502","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1097\/CCM.0000000000005975","article-title":"Angiotensin II for the treatment of refractory shock: A matched analysis.","volume":"51","author":"Smith","year":"2023","journal-title":"Crit Care Med"},{"key":"R20-20250502","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/micc.12120","article-title":"Roles of coagulation and fibrinolysis in angiotensin II-enhanced microvascular thrombosis.","volume":"21","author":"Senchenkova","year":"2014","journal-title":"Microcirculation"},{"key":"R21-20250502","first-page":"571","article-title":"Angiotensin II via AT1 receptor accelerates arterial thrombosis in renovascular hypertensive rats.","volume":"56","author":"Kami\u0144ska","year":"2005","journal-title":"J Physiol Pharmacol"},{"key":"R22-20250502","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13054-020-2733-x","article-title":"Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock.","volume":"24","author":"Bellomo","year":"2020","journal-title":"Crit Care"},{"key":"R23-20250502","first-page":"559","article-title":"The impact of deep vein thrombosis in critically ill patients: A meta-analysis of major clinical outcomes.","volume":"13","author":"Malato","year":"2015","journal-title":"Blood Transfus"},{"key":"R24-20250502","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1186\/s13054-015-1003-9","article-title":"Venous thromboembolism in the ICU: Main characteristics, diagnosis and thromboprophylaxis.","volume":"19","author":"Minet","year":"2015","journal-title":"Crit Care"},{"key":"R25-20250502","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa1014475","article-title":"Dalteparin versus unfractionated heparin in critically ill patients.","volume":"364","author":"Cook","year":"2011","journal-title":"N Engl J Med"},{"key":"R26-20250502","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3390\/hematolrep15020024","article-title":"Risk of thrombosis during and after a SARS-CoV-2 infection: Pathogenesis, diagnostic approach, and management.","volume":"15","author":"Sutanto","year":"2023","journal-title":"Hematol Rep"},{"key":"R27-20250502","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.thromres.2020.04.013","article-title":"Incidence of thrombotic complications in critically ill ICU patients with COVID-19.","volume":"191","author":"Klok","year":"2020","journal-title":"Thromb Res"}],"container-title":["Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCM.0000000000006433","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T18:01:13Z","timestamp":1746208873000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCM.0000000000006433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,15]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/ccm.0000000000006433","relation":{},"ISSN":["0090-3493","1530-0293"],"issn-type":[{"value":"0090-3493","type":"print"},{"value":"1530-0293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,15]]}}}